馬飛，1976年生，籍貫江蘇鹽城，腫瘤內(nèi)科學(xué)家，中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院主任醫(yī)師，博士生導(dǎo)師，教育部國(guó)家級(jí)重大人才項(xiàng)目入選者。1994年考入中國(guó)協(xié)和醫(yī)科大學(xué)（現(xiàn)北京協(xié)和醫(yī)學(xué)院）臨床醫(yī)學(xué)（八年制）專業(yè)，2002年獲得臨床醫(yī)學(xué)博士學(xué)位。2002年進(jìn)入中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院工作，從事實(shí)體腫瘤藥物治療的臨床與研究工作，2016年任主任醫(yī)師。

長(zhǎng)期致力于乳腺癌等實(shí)體瘤的基礎(chǔ)、臨床及轉(zhuǎn)化研究。在腫瘤創(chuàng)新藥物臨床與轉(zhuǎn)化研究、腫瘤轉(zhuǎn)移與耐藥機(jī)制研究、液體活檢與精準(zhǔn)診療研究、腫瘤大數(shù)據(jù)研究等領(lǐng)域開展了系列工作。

久久综合九色欧美综合狠狠_伊人热热久久原色播放WWW_成A人片亚洲日本久久_久久不见久久见免费影院www日本_97久久精品人人做人人爽,又色又爽又黄的视频在线观看,狼群影院视频在线观看高清版,亚洲AV无码精品网站性色,国产乱码久久久久久红粉影视,精品国产乱码久久久久久一区二区,国产精品免费视频网站,国产A级毛片久久久久久精品,一级特黄高清aaaa大片,亚洲中文字幕欧美一区,久久精品国产99久久狂热,黑人巨大精品欧美_黑人巨大精品欧美黑寡妇_黑人巨大精品欧美一区二区_黑人巨大精品欧美一区二区免费_黑人巨大跨种族video_黑人巨大无码中文字幕无码_黑人巨茎大战俄罗斯美女_黑人巨茎大战俄罗斯美女,中文字幕av不卡|亚洲欧美国产另类|天天干在线播放|日韩黄视频|欧美七区|可以免费看毛片的网站|黄色片在线|国产精品96久久久久久

1. Yuanyuan Zhang#, Hongyan Chen#, Hongnan Mo#, Xueda Hu#, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu, Tianyi Qian, Binghe Xu*, Fei Ma*, Zemin Zhang*, Zhihua Liu*. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021, 39(12):1578-1593 (IF=38.585)

2. Zongbi Yi#, Fei Ma*, Guohua Rong, Binliang Liu, Yanfang Guan, Jin Li, Xiaoying Sun, Wenna Wang, Xiuwen Guan, Hongnan Mo, Jiani Wang, Haili Qian, Binghe Xu*. The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduct Target Ther. 2021, 6(1):251. (IF=38.104)

3. Binghe Xu#*, Min Yan#, Fei Ma#, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu, Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou, PHOEBE Investigators. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021, 22(3):351-360. (IF=54.433)

4. Hui Li#, Jinsong Wang, Zongbi Yi, Chunxiao Li, Haijuan Wang, Jingyao Zhang, Ting Wang, Peng Nan, Feng Lin, Dongkui Xu, Haili Qian*, Fei Ma*. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. Eur J Cancer. 2021, 145:92-108. (IF=10.002).

5. Hui-Yao Huang#, Da-Wei Wu#, Fei Ma#, Zhi-Lei Liu, Ju-Fang Shi, Xia Chen, Shu-Hang Wang, Hong Fang, Ying Bai, Yue Yu, Yuan Fang, Chao Sun, Qi Fan, Ying Wu, Rui-Hua Fan, Cai-Yun Zhou, Bao-Xia He, Min Dai, Ning Li*, Bing-He Xu, Yan Sun, Jie He. Availability of anticancer biosimilars in 40 countries. Lancet Oncol. 2020, 21(2):197-201. (IF=41.316)

6. Jian Liu #, Chunxiao Li #, Jinsong Wang #, Dongkui Xu#, Haijuan Wang, Ting Wang, Lina Li, Hui Li, Peng Nan, Jingyao Zhang, Yang Wang, Changzhi Huang, Dong Chen, Yi Zhang, Tao Wen*, Qimin Zhan*, Fei Ma*, Haili Qian*. Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing. Nat Commun. 2020 Sep 8;11(1):4455. (IF=14.919).

7. Fei Ma#*, Yanfang Guan#, Zongbi Yi#, Lianpeng Chang#, Qiao Li, Shanshan Chen, Wenjie Zhu, Xiuwen Guan, Chunxiao Li, Haili Qian, Xuefeng Xia, Ling Yang, Jianjun Zhang, Hatim Husain, Zhongxing Liao, Andrew Futreal, Jian Huang, Xin Yi*, Binghe Xu*. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020, 146(5):1359-1368. (IF=7.316)

8. Fei Ma#, Quchang Ouyang#, Wei Li, Zefei Jiang, Zhongsheng Tong, Yunjiang Liu, Huiping Li, Shiying Yu, Jifeng Feng, Shusen Wang, Xichun Hu, Jianjun Zou, Xiaoyu Zhu, Binghe Xu*. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. J Clin Oncol. 2019, 37(29):2610-2619. (IF=32.956)

9. Qiao Li#, Xiuwen Guan#, Shanshan Chen, Zongbi Yi, Bo Lan, Puyuan Xing, Ying Fan, Jiayu Wang, Yang Luo, Peng Yuan, Ruigang Cai, Pin Zhang, Qing Li, Dafang Zhong, Yifan Zhang, Jianjun Zou, Xiaoyu Zhu, Fei Ma*, Binghe Xu*. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clin Cancer Res. 2019, 25(17):5212-5220. (IF=10.107)

10. Fei Ma#, Qiao Li#, Shanshan Chen, Wenjie Zhu, Ying Fan, Jiayu Wang, Yang Luo, Puyuan Xing, Bo Lan, Meiying Li, Zongbi Yi, Ruigang Cai, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu*. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. 2017, J Clin Oncol. 35(27):3105-3112. (IF=26.303).